B of A Securities Maintains Buy on Insmed, Raises Price Target to $213

Benzinga Newsdesk www.benzinga.com Positive 77.8%

Neg 0% Neu 0% Pos 77.8%

B of A Securities analyst Jason Zemansky maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $211 to $213.